AREC vs. BVXP, 4BB, TILS, VSN, SCLP, MPH, OBI, ORPH, IMM, and REDX
Should you be buying Arecor Therapeutics stock or one of its competitors? The main competitors of Arecor Therapeutics include Bioventix (BVXP), 4basebio (4BB), Tiziana Life Sciences (TILS), Verseon (VSN), Scancell (SCLP), Mereo BioPharma Group plc (MPH.L) (MPH), Ondine Biomedical (OBI), Open Orphan (ORPH), ImmuPharma (IMM), and Redx Pharma (REDX). These companies are all part of the "biotechnology" industry.
Arecor Therapeutics vs. Its Competitors
Bioventix (LON:BVXP) and Arecor Therapeutics (LON:AREC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.
Bioventix has higher revenue and earnings than Arecor Therapeutics. Arecor Therapeutics is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.
Bioventix has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Arecor Therapeutics has a beta of -0.18, indicating that its share price is 118% less volatile than the S&P 500.
32.4% of Bioventix shares are held by institutional investors. Comparatively, 10.3% of Arecor Therapeutics shares are held by institutional investors. 6.1% of Bioventix shares are held by company insiders. Comparatively, 4.8% of Arecor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Bioventix has a net margin of 59.51% compared to Arecor Therapeutics' net margin of -176.89%. Bioventix's return on equity of 69.09% beat Arecor Therapeutics' return on equity.
In the previous week, Bioventix's average media sentiment score of 0.67 beat Arecor Therapeutics' score of 0.00 indicating that Bioventix is being referred to more favorably in the media.
Summary
Bioventix beats Arecor Therapeutics on 12 of the 12 factors compared between the two stocks.
Get Arecor Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AREC and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arecor Therapeutics Competitors List
Related Companies and Tools
This page (LON:AREC) was last updated on 10/9/2025 by MarketBeat.com Staff
